

2017

1. Beaumont, M., Jaoui, D., Douard, V., Mat, D., Koeth, F., Goustard, B., Mayeur, C., Mondot, S., Hovaghimian, A., Feunteun, S.L., Chaumontet, C., Davila, A.-M., Tomé, D., Souchon, I., Michon, C., Fromentin, G., Blachier, F., and Leclerc, M. Structure of protein emulsion in food impacts intestinal microbiota, caecal luminal content composition and distal intestine characteristics in rats. *Mol. Nutr. Food Res.* (2017).
2. Bertrand, A., Rondenot, C., Masliah-Planchon, J., Leblond, P., de la Fourchardière, A., Pissaloux, D., Aït-Raïs, K., Lequin, D., Jouvet, A., Freneaux, P., Sevestre, H., Ranchere-Vince, D., Tauziede-Espariat, A., Maurage, C.-A., Silva, K., Pierron, G., Delattre, O., Varlet, P., Frappaz, D., and **Bourdeaut, F.** Rhabdoid component emerging as a subclonal evolution of paediatric glioneuronal tumours. *Neuropathol Appl Neurobiol.* (2017).
3. Boeva, V., Louis-Brennetot, C., Peltier, A., Durand, S., Pierre-Eugène, C., Raynal, V., Etchevers, H.C., Thomas, S., Lermine, A., Daudigeos-Dubus, E., Georger, B., Orth, M.F., Grünewald, T.G.P., Diaz, E., Ducos, B., **Surdez, D.**, Carcaboso, A.M., Medvedeva, I., Deller, T., Combaret, V., Lapouble, E., Pierron, G., Grossetête-Lalami, S., **Baulande, S.**, **Schleiermacher, G.**, Barillot, E., Rohrer, H., Delattre, O., and Janoueix-Lerosey, I. Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. *Nat. Genet.* (2017).
4. Borensztein, M., Syx, L., Ancelin, K., Diabangouaya, P., Picard, C., Liu, T., Liang, J.-B., Vassilev, I., Galupa, R., Servant, N., Barillot, E., Surani, A., Chen, C.-J., and Heard, E. Xist-dependent imprinted X inactivation and the early developmental consequences of its failure. *Nat. Struct. Mol. Biol.* (2017).
5. Costa, A. **Kieffer Y.**, Scholer-Dahirel A., Bourachot B., **Cardon M.**, Sirven P., Pelon F., Furhmann L., Kondratova M., Kuperstein I., Zinovyev A., Magagna I., Givel AM., Parrini M., Soumelis V., Vincent-Salomon A. and Mechta-Grigoriou F. Mechanisms of immunosuppression mediated by fibroblast subsets in human breast cancer. (*Submitted*)
6. Drak Alsibai, K., and **Meseure, D.** Tumor microenvironment and noncoding RNAs as co-drivers of epithelial–mesenchymal transition and cancer metastasis. *Dev. Dyn.* (2017).
7. Givel, AM, **Kieffer Y.**, Scholer-Dahirel A., Sirven P., **Cardon M.**, Pelon F., Gentric G., Costa A., Bonneau C. Mieulet V., Vincent-Salomon A and Mechta-Grigoriou F. miR-200-regulated CXCL12beta promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. (*Under revision*)
8. Greenberg, M.V.C., Glaser, J., Borsos, M., Marjou, F.E., Walter, M., Teissandier, A., and Bourc'his, D. Transient transcription in the early embryo sets an epigenetic state that programs postnatal growth. *Nat Genet.* (2017).
9. He, T., **Surdez, D.**, Rantala, J.K., Haapa-Paananen, S., Ban, J., Kauer, M., Tomazou, E., Fey, V., Alonso, J., Kovar, H., Delattre, O., and Iljin, K. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability. *Gene.* (2017).
10. Mobuchon, L., Battistella, A., Bardel, C., Scelo, G., Renoud, A., Houy, A., Cassoux, N., **Milder, M.**, Cancel-Tassin, G., Cussenot, O., Delattre, O., Besse, C., Boland, A., Deleuze, J.-F., Cox, D.G., and Stern, M.-H. A GWAS in uveal melanoma identifies risk polymorphisms in the CLPTM1L locus. *npj Genomic Medicine.* (2017).
11. Ng, C.K.Y., Bidard, F.-C., Piscuoglio, S., Geyer, F.C., Lim, R.S., Buijn, I. de, Shen, R., Pareja, F., Berman, S.H., Wang, L., Pierga, J.-Y., Vincent-Salomon, A., Viale, A., Norton, L., Sigal, B., Weigelt, B., Cottu, P., and Reis-Filho, J.S. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases. *Clin Cancer Res.* (2017).

12. Portoso, M., Ragazzini, R., Brenčič, Ž., Moiani, A., Michaud, A., Vassilev, I., Wassef, M., Servant, N., Sargueil, B., and Margueron, R. PRC2 is dispensable for HOTAIR-mediated transcriptional repression. *EMBO J.* (2017).
13. **Richer, W.**, Masliah-Planchon, J., Clement, N., Jimenez, I., Maillot, L., Gentien, D., Albaud, B., Chemlali, W., Galant, C., Larousserie, F., Boudou-Rouquette, P., Leruste, A., Chauvin, C., Han, Z.Y., Coindre, J.-M., Varlet, P., Freneaux, P., Ranchère-Vince, D., Delattre, O., and **Bourdeaut, F.** Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancers. *Oncotarget.* (2017).
14. Sheffield, N.C., Pierron, G., Klughammer, J., Datlinger, P., Schönegger, A., Schuster, M., Hadler, J., **Surdez, D.**, Guillemot, D., Lapouble, E., Freneaux, P., Champigneulle, J., Bouvier, R., Walder, D., Ambros, I.M., Hutter, C., Sorz, E., Amaral, A.T., de Álava, E., Schallmoser, K., Strunk, D., Rinner, B., Liegl-Atzwanger, B., Huppertz, B., Leithner, A., de Pinieux, G., Terrier, P., Laurence, V., Michon, J., Ladenstein, R., Holter, W., Windhager, R., Dirksen, U., Ambros, P.F., Delattre, O., Kovar, H., Bock, C., and Tomazou, E.M. DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. *Nat. Med.* (2017).
15. Tauziède-Espariat, A., Masliah-Planchon, J., Brugières, L., Puget, S., Dufour, C., Schneider, P., Laquerrière, A., Frebourg, T., Bodet, D., Lechapt-Zalcman, E., Pierron, G., Delattre, O., Varlet, P., and **Bourdeaut, F.** Deep intronic hotspot variant unraveling rhabdoid tumor predisposition syndrome in two patients with atypical teratoid and rhabdoid tumor. *Eur J Hum Genet.* (2017).

2016

1. **Alsafadi, S.**, Houy, A., Battistella, A., Popova, T., Wassef, M., Henry, E., Tirode, F., Constantinou, A., Piperno-Neumann, S., Roman Roman, S., Dutertre, M., and Stern, M.-H. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. *Nat Commun.* (2016).
2. Barau, J., Teissandier, A., Zamudio, N., Roy, S., Nalesso, V., Hérault, Y., Guillou, F., and Bourc'his, D. The DNA methyltransferase DNMT3C protects male germ cells from transposon activity. *Science.* (2016).
3. Batista, L., Bourachot, B., Mateescu, B., **Reyal, F.**, and Mechta-Grigoriou, F. Regulation of miR-200c/141 expression by intergenic DNA-looping and transcriptional read-through. *Nat Commun.* (2016).
4. Bertucci, F., Fekih, M., Autret, A., Petit, T., Dalenc, F., Levy, C., Romieu, G., Bonneterre, J., Ferrero, J.-M., Kerbrat, P., Soulie, P., Mouret-Reynier, M.-A., Bachelot, T., Lerebours, F., Eymard, J.-C., Deblock, M., Lortholary, A., Hardy-Bessard, A.-C., Barthelemy, P., Bonnefoi, H., Charafe-Jauffret, E., Bidard, F.-C., Viens, P., Lemonnier, J., and Pierga, J.-Y. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. *Lancet Oncol.* (2016).
5. Besse, B., Charrier, M., Lapierre, V., Dansin, E., Lantz, O., Planchard, D., Le Chevalier, T., Livartoski, A., Barlesi, F., Laplanche, A., Ploix, S., Vimond, N., Peguillet, I., Théry, C., Lacroix, L., Zoernig, I., Dhodapkar, K., Dhodapkar, M., Viaud, S., Soria, J.-C., Reiners, K.S., Pogge von Strandmann, E., Vély, F., Rusakiewicz, S., Eggermont, A., Pitt, J.M., Zitvogel, L., and Chaput, N. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. *Oncoimmunology.* (2016).
6. Bettoun, A., Joffre, C., Zago, G., **Surdez, D.**, Vallerand, D., Gundogdu, R., Sharif, A.A.D., Gomez, M., Cascone, I., Meunier, B., White, M.A., Codogno, P., Parrini, M.C.,

- Camonis, J.H., and Hergovich, A. Mitochondrial clearance by the STK38 kinase supports oncogenic Ras-induced cell transformation. *Oncotarget*. (2016).
7. **Bourdeaut, F.** Right to know and right to ignore in paediatric oncogenetics: Identifying biological causes, or seeking for meaning? *Eur. J. Cancer*. (2016).
 8. Chen, D.L., Humphreys, A., Turnbull, D.L., Bown, D.N., and Tweddle, P.D. Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse. *Oncotarget*. (2016).
 9. Chicard, M., Boyault, S., Colmet Daage, L., **Richer, W.**, Gentien, D., Pierron, G., Lapouble, E., **Bellini, A.**, Clement, N., Iacono, I., Bréjon, S., Carrere, M., Reyes, C., Hocking, T., **Bernard, V.**, Peuchmaur, M., Corradini, N., Faure-Conter, C., Coze, C., Plantaz, D., Defachelles, A.S., Thebaud, E., Gambart, M., Millot, F., Valteau-Couanet, D., Michon, J., Puisieux, A., Delattre, O., Combaret, V., and **Schleiermacher, G.** Genomic copy number profiling using circulating free tumor DNA highlights heterogeneity in neuroblastoma. *Clin. Cancer Res*. (2016).
 10. Decock, A., Ongenaert, M., Cannoodt, R., Verniers, K., De Wilde, B., Laureys, G., Van Roy, N., Berbegall, A.P., Bienertova-Vasku, J., Bown, N., Clément, N., Combaret, V., Haber, M., Hoyoux, C., Murray, J., Noguera, R., Pierron, G., **Schleiermacher, G.**, Schulte, J.H., Stallings, R.L., Tweddle, D.A., Children's Cancer and Leukaemia Group (CCLG), De Preter, K., Speleman, F., and Vandesompele, J. Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma. *Oncotarget*. (2016).
 11. Deveau, P., Daage, L.C., Oldridge, D., **Bernard, V.**, **Bellini, A.**, Chicard, M., Clement, N., Lapouble, E., Combaret, V., Boland, A., Meyer, V., Deleuze, J.-F., Janoueix-Lerosey, I., Barillot, E., Delattre, O., Maris, J., **Schleiermacher, G.**, and Boeva, V. Clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction. *bioRxiv*. (2016).
 12. Duhil de Bénazé, G., Iserin, F., Durand, P., **Schleiermacher, G.**, and Orbach, D. A Dilated Cardiomyopathy Revealing a Neuroblastoma: Which Link? *J. Pediatr. Hematol. Oncol*. (2016).
 13. Ebner, H., Hayn, D., Falgenhauer, M., Nitzlader, M., **Schleiermacher, G.**, Haupt, R., Erminio, G., Defferrari, R., Mazzocco, K., Kohler, J., Tonini, G.P., Ladenstein, R., and Schreier, G. Piloting the European Unified Patient Identity Management (EUPID) Concept to Facilitate Secondary Use of Neuroblastoma Data from Clinical Trials and Biobanking. *Stud Health Technol Inform*. (2016).
 14. Frühwald, M.C., Biegel, J.A., **Bourdeaut, F.**, Roberts, C.W.M., and Chi, S.N. Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies. *Neuro-oncology*. (2016).
 15. Gendrel, A.-V., Marion-Poll, L., Katoh, K., and Heard, E. Random monoallelic expression of genes on autosomes: Parallels with X-chromosome inactivation. *Semin. Cell Dev. Biol*. (2016).
 16. Ghirelli, C., Sadacca, B., **Reyal, F.**, Zollinger, R., Michea, P., Sirven, P., Pattarini, L., Martínez-Cingolani, C., **Guillot-Delost, M.**, **Nicolas, A.**, Scholer-Dahirel, A., and Soumelis, V. No evidence for TSLP pathway activity in human breast cancer. *Oncoimmunology*. (2016).
 17. Giorgetti, L., and Heard, E. Closing the loop: 3C versus DNA FISH. *Genome Biol*. (2016).
 18. Giorgetti, L., Lajoie, B.R., Carter, A.C., Attia, M., Zhan, Y., Xu, J., Chen, C.J., Kaplan, N., Chang, H.Y., Heard, E., and Dekker, J. Structural organization of the inactive X chromosome in the mouse. *Nature*. (2016).
 19. Gruel, N., Fuhrmann, L., Lodillinsky, C., Benhamo, V., Mariani, O., Cédénat, A., Arnould, L., Macgrogan, G., Sastre-Garau, X., Chavrier, P., Delattre, O., and Vincent-

- Salomon, A. LIN7A is a major determinant of cell-polarity defects in breast carcinomas. *Breast Cancer Res.* (2016).
20. Grünewald, T.G.P., and Delattre, O. Cooperation between somatic mutations and germline susceptibility variants in tumorigenesis - a dangerous liaison. *Mol Cell Oncol.* (2016).
 21. Grünewald, T.G.P., Gilardi-Hebenstreit, P., Charnay, P., and Delattre, O. [Cooperation between a somatic mutation and a genetic susceptibility variant in Ewing sarcoma]. *Med Sci (Paris).* (2016).
 22. Gruosso, T., Mieulet, V., **Cardon, M.**, Bourachot, B., Kieffer, Y., Devun, F., Dubois, T., Dutreix, M., Vincent-Salomon, A., Miller, K.M., and Mechta-Grigoriou, F. Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients. *EMBO Mol Med.* (2016).
 23. **Guillot-Delost, M.**, Guilleré, L., Berger, F., Ventre, A., Michea, P., Sirven, P., Pattarini, L., Scholer-Dahirel, A., Kebir, F.-Z., Huerre, M., Chouchane-Mlik, O., Lappartient, E., Rodriguez, J., Jouffroy, T., Klijanienko, J., **Nicolas, A.**, Sastre-Garau, X., Honorio, S., Mosseri, V., Le Peltier, N., Sablin, M.-P., **Le Tourneau, C.**, Tartour, É., Badoual, C., and Soumelis, V. Ligand-receptor dissociated expression explains high TSLP without prognostic impact in human primary head and neck squamous cell carcinoma. *Oncoimmunology.* (2016).
 24. Gurard-Levin, Z.A., Wilson, L.O.W., Pancaldi, V., Postel-Vinay, S., Sousa, F.G., Reyes, C., Marangoni, E., Gentien, D., Valencia, A., Pommier, Y., Cottu, P., and Almouzni, G. Chromatin regulators as a guide for cancer treatment choice. *Mol. Cancer Ther.* (2016).
 25. Hayn, D., Falgenhauer, M., Kropf, M., Nitzlnader, M., Welte, S., Ebner, H., Ladenstein, R., **Schleiermacher, G.**, Hero, B., and Schreier, G. IT Infrastructure for Merging Data from Different Clinical Trials and Across Independent Research Networks. *Stud Health Technol Inform.* (2016).
 26. Heard, E. 3D solutions to complex gene regulation. *Nat. Rev. Mol. Cell Biol.* (2016).
 27. Holmes, A., Lameiras, S., Jeannot, E., Marie, Y., Castera, L., Sastre-Garau, X., and **Nicolas, A.** Mechanistic signatures of HPV insertions in cervical carcinomas. *Genome Med.* (2016).
 28. Iakovishina, D., Janoueix-Lerosey, I., Barillot, E., Regnier, M., and Boeva, V. SV-Bay: structural variant detection in cancer genomes using a Bayesian approach with correction for GC-content and read mappability. *Bioinformatics.* (2016).
 29. Kopanska, K.S., Alcheikh, Y., Staneva, R., Vignjevic, D., and Betz, T. Tensile Forces Originating from Cancer Spheroids Facilitate Tumor Invasion. *PLoS ONE.* (2016).
 30. Laé, M., La Rosa, P., Mandel, J., **Reyal, F.**, Hupé, P., Terrier, P., and Couturier, J. Whole-genome profiling helps to classify phyllodes tumours of the breast. *J. Clin. Pathol.* (2016).
 31. Laureau, R., Loeillet, S., Salinas, F., Bergström, A., Legoix-Né, P., Liti, G., and **Nicolas, A.** Extensive Recombination of a Yeast Diploid Hybrid through Meiotic Reversion. *PLoS Genet.* (2016).
 32. Lefort, S., Thuleau, A., Kieffer, Y., Sirven, P., Bieche, I., Marangoni, E., Vincent-Salomon, A., and Mechta-Grigoriou, F. CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients. *Oncogene.* (2016).
 33. Martignetti, L., Calzone, L., Bonnet, E., Barillot, E., and Zinovyev, A. ROMA: Representation and Quantification of Module Activity from Target Expression Data. *Front Genet.* (2016).
 34. Masliah-Planchon, J., Machet, M.-C., Fréneaux, P., Jourdain, A., Mortemousque, I., Raïs, K.A., Ballet, S., Jouvét, A., Figarella-Branger, D., Delattre, O., and **Bourdeaut, F.** SMARCA4-Mutated Atypical Teratoid/Rhabdoid Tumor with Retained BRG1 Expression. *Pediatr Blood Cancer.* (2016).

35. Matthay, K.K., Maris, J.M., **Schleiermacher, G.**, Nakagawara, A., Mackall, C.L., Diller, L., and Weiss, W.A. Neuroblastoma. Nat Rev Dis Primers. (2016).
36. **Meseure, D.**, Vacher, S., Alsibai, K.D., **Nicolas, A.**, Chemlali, W., Caly, M., Lidereau, R., Pasmant, E., Callens, C., and Bieche, I. Expression of ANRIL-Polycomb Complexes-CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value. Mol. Cancer Res. (2016).
37. **Meseure, D.**, Vacher, S., Alsibai, K.D., Trassard, M., **Nicolas, A.**, Leclere, R., Lerebours, F., Guinebretiere, J.M., Marangoni, E., Lidereau, R., and Bieche, I. Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes. Cancer Microenvironment. (2016).
38. **Meseure, D.**, Vacher, S., Lallemand, F., Alsibai, K.D., Hatem, R., Chemlali, W., **Nicolas, A.**, De Koning, L., Pasmant, E., Callens, C., Lidereau, R., Morillon, A., and Bieche, I. Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer. Br. J. Cancer. (2016).
39. Minas, T.Z., **Surdez, D.**, Javaheri, T., Tanaka, M., Howarth, M., Kang, H.-J., Han, J., **Han, Z.-Y.**, Sax, B., Kream, B.E., Hong, S.-H., Çelik, H., Tirode, F., Tuckermann, J., Toretsky, J.A., Kenner, L., Kovar, H., Lee, S., Sweet-Cordero, E.A., Nakamura, T., Moriggi, R., Delattre, O., and Üren, A. Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. Oncotarget. (2016).
40. Morgenstern, D.A., London, W.B., Stephens, D., Volchenboum, S.L., Simon, T., Nakagawara, A., Shimada, H., **Schleiermacher, G.**, Matthay, K.K., Cohn, S.L., Pearson, A.D.J., and Irwin, M.S. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. Eur. J. Cancer. (2016).
41. Orsi, G.A., Naughtin, M., and Almouzni, G. The Epigenome and Cancer Stem Cell Fate: Connected by a Linker Histone Variant. Cell Stem Cell. (2016).
42. Pearson, A.D.J., Herold, R., Rousseau, R., Copland, C., Bradley-Garelik, B., Binner, D., Capdeville, R., Caron, H., Carleer, J., Chesler, L., Georger, B., Kearns, P., Marshall, L.V., Pfister, S.M., **Schleiermacher, G.**, Skolnik, J., Spadoni, C., Sterba, J., van den Berg, H., Uttenreuther-Fischer, M., Witt, O., Norga, K., Vassal, G., and Members of Working Group 1 of the Paediatric Platform of ACCELERATE Implementation of mechanism of action biology-driven early drug development for children with cancer. Eur. J. Cancer. (2016).
43. Pincez, T., Clément, N., Lapouble, E., Pierron, G., Kamal, M., Bieche, I., **Bernard, V.**, Fréneaux, P., Michon, J., Orbach, D., Aerts, I., Pacquement, H., **Bourdeaut, F.**, Jiménez, I., Thébaud, E., Oudot, C., Vérité, C., Taque, S., Owens, C., Doz, F., **Le Tourneau, C.**, Delattre, O., and **Schleiermacher, G.** Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors. Pediatr Blood Cancer. (2016).
44. Pinto, N., Mayfield, J.R., Raca, G., Applebaum, M.A., Chlenski, A., Sukhanova, M., Bagatell, R., Irwin, M.S., Little, A., Rawwas, J., Gosiengfiao, Y., Delattre, O., Janoueix-Lerosey, I., Lapouble, E., **Schleiermacher, G.**, and Cohn, S.L. Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence. Pediatr Blood Cancer. (2016).
45. Popova, T., Manié, E., Boeva, V., Battistella, A., Goundiam, O., Smith, N.K., Mueller, C.R., Raynal, V., Mariani, O., Sastre-Garau, X., and Stern, M.-H. Ovarian cancers harboring inactivating mutations in CDK12 display a distinct genomic instability pattern characterized by large tandem duplications. Cancer Res. (2016).

46. Provost, C., Prignon, A., Cazes, A., Combaret, V., Delattre, O., Janoueix-Lerosey, I., Montravers, F., and Talbot, J.-N. 68Ga-DOTATOC and FDG PET Imaging of Preclinical Neuroblastoma Models. *Anticancer Res.* (2016).
47. Rico, Y.A.P., Boeva, V., Mallory, A.C., Bitetti, A., Majello, S., Barillot, E., and Shkumatava, A. Comparative analyses of super-enhancers reveal conserved elements in vertebrate genomes. *Genome Res.* (2016).
48. Scalabre, A., Bergeron, C., Brioude, F., Dainese, L., Cropet, C., Coulomb L'hermine, A., Pasqualini, C., Auber, F., Verschuur, A., **Schleiermacher, G.**, Le Bouc, Y., Audry, G., and Irtan, S. Is Nephron Sparing Surgery Justified in Wilms Tumor With Beckwith-Wiedemann Syndrome or Isolated Hemihypertrophy? *Pediatr Blood Cancer.* (2016).
49. **Schoumacher, M.**, Le Corre, S., Houy, A., Mulugeta, E., Stern, M.-H., Roman Roman, S., and Margueron, R. Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status. *Nat. Med.* (2016).
50. Siegfried, A., Bertozzi, A.I., **Bourdeaut, F.**, Sevely, A., Loukh, N., Grison, C., Miquel, C., Lafon, D., Sevenet, N., Pietsch, T., Dufour, C., and Delisle, M.-B. Clinical, pathological, and molecular data on desmoplastic/nodular medulloblastoma: case studies and a review of the literature. *Clin. Neuropathol.* (2016).
51. Walter, M., Teissandier, A., Pérez-Palacios, R., and Bourc'his, D. An epigenetic switch ensures transposon repression upon dynamic loss of DNA methylation in embryonic stem cells. *Elife.* (2016).
52. Wassef, M., and Margueron, R. The Multiple Facets of PRC2 Alterations in Cancers. *J. Mol. Biol.* (2016).
53. Wassef, M., Michaud, A., and Margueron, R. Association between EZH2 expression, silencing of tumor suppressors and disease outcome in solid tumors. *Cell Cycle.* (2016).
54. Wery, M., Describes, M., Vogt, N., Dallongeville, A.-S., Gautheret, D., and Morillon, A. Nonsense-Mediated Decay Restricts LncRNA Levels in Yeast Unless Blocked by Double-Stranded RNA Structure. *Molecular Cell.* (2016)

2015

1. Amirouchene-Angelozzi, N., **Schoumacher, M.**, Stern, M.-H., Cassoux, N., Desjardins, L., Piperno-Neumann, S., Lantz, O., and Roman Roman, S. Upcoming translational challenges for uveal melanoma. *Br. J. Cancer.* (2015).
2. **Bellini, A.**, **Bernard, V.**, Leroy, Q., Rio-Frio, T., Pierron, G., Combaret, V., Lapouble, E., Clement, N., Rubie, H., Thebaud, E., Chastagner, P., Defachelles, A.S., Bergeron, C., Buchbinder, N., Taque, S., Auvrignon, A., Valteau-Couanet, D., Michon, J., Janoueix-Lerosey, I., Delattre, O., and **Schleiermacher, G.** Deep sequencing reveals occurrence of sub-clonal ALK mutations in neuroblastoma at diagnosis. *Clin. Cancer Res.* (2015).
3. Bonnet, E., Viara, E., Kuperstein, I., Calzone, L., Cohen, D.P.A., Barillot, E., and Zinovyev, A. NaviCell Web Service for network-based data visualization. *Nucleic Acids Res.* (2015).
4. Calderaro, J., Masliah-Planchon, J., **Richer, W.**, Maillot, L., Maille, P., Mansuy, L., Bastien, C., de la Taille, A., Bousson, H., Charpy, C., Jourdain, A., Bléchet, C., Pierron, G., Gentien, D., Choudat, L., Tournigand, C., Delattre, O., Allory, Y., and **Bourdeaut, F.** Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas. *Eur. Urol.* (2015).
5. Cappuccio, A., Zollinger, R., Schenk, M., Walczak, A., Servant, N., Barillot, E., Hupé, P., Modlin, R.L., and Soumelis, V. Combinatorial code governing cellular responses to complex stimuli. *Nat Commun.* (2015).

6. Chaligné, R., Popova, T., Mendoza-Parra, M.-A., Saleem, M.-A.M., Gentien, D., Ban, K., Piolot, T., Leroy, O., Mariani, O., Gronemeyer, H., Vincent-Salomon, A., Stern, M.-H., and Heard, E. The inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancer. *Genome Res.* (2015).
7. Combaret, V., Iacono, I., **Bellini, A.**, Bréjon, S., Bernard, V., Marabelle, A., Coze, C., Pierron, G., Lapouble, E., **Schleiermacher, G.**, and Blay, J.Y. Detection of tumor ALK status in neuroblastoma patients using peripheral blood. *Cancer Med.* (2015).
8. Curtit, E., Benhamo, V., Gruel, N., Popova, T., Manie, E., Cottu, P., Mariani, O., Stoppa-Lyonnet, D., Pivot, X., Stern, M.-H., and Vincent-Salomon, A. First description of a sporadic breast cancer in a woman with BRCA1 germline mutation. *Oncotarget.* (2015).
9. Eleveld, T.F., Oldridge, D.A., **Bernard, V.**, Koster, J., Daage, L.C., Diskin, S.J., Schild, L., Bentahar, N.B., **Bellini, A.**, Chicard, M., Lapouble, E., Combaret, V., Legoix-Né, P., Michon, J., Pugh, T.J., Hart, L.S., Rader, J., Attiyeh, E.F., Wei, J.S., Zhang, S., Naranjo, A., Gastier-Foster, J.M., Hogarty, M.D., Asgharzadeh, S., Smith, M.A., Auvil, J.M.G., Watkins, T.B.K., Zwijnenburg, D.A., Ebus, M.E., van Sluis, P., Hakkert, A., van Wezel, E., van der Schoot, C.E., Westerhout, E.M., Schulte, J.H., Tytgat, G.A., Dolman, M.E.M., Janoueix-Lerosey, I., Gerhard, D.S., Caron, H.N., Delattre, O., Khan, J., Versteeg, R., **Schleiermacher, G.**, Molenaar, J.J., and Maris, J.M. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. *Nat. Genet.* (2015).
10. Galupa, R., and Heard, E. X-chromosome inactivation: new insights into cis and trans regulation. *Curr. Opin. Genet. Dev.* (2015).
11. Ghirelli, C., **Reyal, F.**, Jeanmougin, M., Zollinger, R., Sirven, P., Michea, P., Caux, C., Bendriss-Vermare, N., Donnadiou, M.-H., Caly, M., Fourchette, V., Vincent-Salomon, A., Sigal, B., Sastre-Garau, X., and Soumelis, V. Breast Cancer Cell-Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes. *Cancer Res.* (2015).
12. Grünewald, T.G.P., **Bernard, V.**, Gilardi-Hebenstreit, P., Raynal, V., **Surdez, D.**, Aynaud, M.-M., Mirabeau, O., Cidre-Aranaz, F., Tirode, F., Zaidi, S., Perot, G., Jonker, A.H., Lucchesi, C., Le Deley, M.-C., Oberlin, O., Marec-Bérard, P., Véron, A.S., Reynaud, S., Lapouble, E., Boeva, V., Frio, T.R., Alonso, J., Bhatia, S., Pierron, G., Cancel-Tassin, G., Cussenot, O., Cox, D.G., Morton, L.M., Machiela, M.J., Chanock, S.J., Charnay, P., and Delattre, O. Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. *Nature Genetics.* (2015).
13. Gruosso, T., Garnier, C., Abelanet, S., Kieffer, Y., Lemesre, V., Bellanger, D., Bieche, I., Marangoni, E., Sastre-Garau, X., Mieulet, V., and Mechta-Grigoriou, F. MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas. *Nat Commun.* (2015).
14. Kuperstein, I., Bonnet, E., Nguyen, H.-A., Cohen, D., Viara, E., Grieco, L., Fourquet, S., Calzone, L., Russo, C., Kondratova, M., Dutreix, M., Barillot, E., and Zinovyev, A. Atlas of Cancer Signalling Network: a systems biology resource for integrative analysis of cancer data with Google Maps. *Oncogenesis.* (2015).
15. Le Loarer, F., Watson, S., Pierron, G., de Montpreville, V.T., Ballet, S., Firmin, N., Auguste, A., Pissaloux, D., Boyault, S., Painsavoine, S., Dechelotte, P.J., Besse, B., Vignaud, J.M., Brevet, M., Fadel, E., **Richer, W.**, Treilleux, I., Masliah-Planchon, J., Devouassoux-Shisheboran, M., Zalzman, G., Allory, Y., **Bourdeaut, F.**, Thivolet-Bejui, F., Ranchere-Vince, D., Girard, N., Lantuejoul, S., Galateau-Sallé, F., Coindre, J.M., Leary, A., Delattre, O., Blay, J.Y., and Tirode, F. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. *Nat Genet.* (2015).

16. Martignetti, L., Tesson, B., Almeida, A., Zinovyev, A., Tucker, G.C., Dubois, T., and Barillot, E. Detection of miRNA regulatory effect on triple negative breast cancer transcriptome. BMC Genomics. (2015).
17. Masliah-Planchon, J., Bièche, I., Guinebretière, J.-M., **Bourdeaut, F.**, and Delattre, O. SWI/SNF Chromatin Remodeling and Human Malignancies. Annu. Rev. Pathol. (2015).
18. **Meseure, D.**, Drak Alsibai, K., **Nicolas, A.**, Bieche, I., and Morillon, A. Long Noncoding RNAs as New Architects in Cancer Epigenetics, Prognostic Biomarkers, and Potential Therapeutic Targets. Biomed Res Int. (2015).
19. Montes de Oca, R., Gurard-Levin, Z.A., Berger, F., Rehman, H., Martel, E., Corpet, A., de Koning, L., Vassias, I., Wilson, L.O.W., **Meseure, D.**, **Reyal, F.**, Savignoni, A., Asselain, B., Sastre-Garau, X., and Almouzni, G. The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma. Molecular Oncology. (2015).
20. Servant, N., Varoquaux, N., Lajoie, B.R., Viara, E., Chen, C.-J., Vert, J.-P., Heard, E., Dekker, J., and Barillot, E. HiC-Pro: an optimized and flexible pipeline for Hi-C data processing. Genome Biol. (2015).
21. Soumelis, V., Pattarini, L., Michea, P., and Cappuccio, A. Systems approaches to unravel innate immune cell diversity, environmental plasticity and functional specialization. Curr. Opin. Immunol. (2015).
22. Touzot, M., Dahirel, A., Cappuccio, A., Segura, E., Hupé, P., and Soumelis, V. Using Transcriptional Signatures to Assess Immune Cell Function: From Basic Mechanisms to Immune-Related Disease. J. Mol. Biol. (2015).
23. Wassef, M., Rodilla, V., Teissandier, A., Zeitouni, B., Gruel, N., Sadacca, B., Irondelle, M., Charruel, M., Ducos, B., Michaud, A., Caron, M., Marangoni, E., Chavrier, P., **Le Tourneau, C.**, Kamal, M., Pasmant, E., Vidaud, M., Servant, N., **Reyal, F.**, **Meseure, D.**, Vincent-Salomon, A., Fre, S., and Margueron, R. Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis. Genes Dev. (2015).

2014

1. **Bourdeaut, F.**, Chi, S.N., and Frühwald, M.C. Rhabdoid tumors: integrating biological insights with clinical success: a report from the SMARCB1 and Rhabdoid Tumor Symposium, Paris, December 12-14, 2013. Cancer Genet. (2014).
2. **Bourdeaut, F.**, Miquel, C., **Richer, W.**, Grill, J., Zerah, M., Grison, C., Pierron, G., Amiel, J., Krucker, C., Radvanyi, F., Brugieres, L., and Delattre, O. Rubinstein-Taybi syndrome predisposing to non-WNT, non-SHH, group 3 medulloblastoma. Pediatr Blood Cancer. (2014).
3. Cazes, A., Lopez-Delisle, L., Tsarovina, K., Pierre-Eugène, C., De Preter, K., Peuchmaur, M., **Nicolas, A.**, Provost, C., Louis-Brennetot, C., Daveau, R., Kumps, C., Cascone, I., **Schleiermacher, G.**, Prignon, A., Speleman, F., Rohrer, H., Delattre, O., and Janoueix-Lerosey, I. Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma. Oncotarget. (2014).
4. Chaligné, R., and Heard, E. X-chromosome inactivation in development and cancer. FEBS Lett. (2014).
5. Cohen-Gogo, S., Cellier, C., Coindre, J.-M., Mosseri, V., Pierron, G., Guillemet, C., Italiano, A., Brugières, L., Orbach, D., Laurence, V., Delattre, O., and Michon, J. Ewing-like sarcomas with BCOR-CCNB3 fusion transcript: a clinical, radiological and pathological retrospective study from the Société Française des Cancers de L'Enfant. Pediatr Blood Cancer. (2014).

6. Costa, A., Scholer-Dahirel, A., and Mechta-Grigoriou, F. The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. *Semin. Cancer Biol.* (2014).
7. da Rocha, S.T., Boeva, V., Escamilla-Del-Arenal, M., Ancelin, K., Granier, C., Matias, N.R., Sanulli, S., Chow, J., Schulz, E., Picard, C., Kaneko, S., Helin, K., Reinberg, D., Stewart, A.F., Wutz, A., Margueron, R., and Heard, E. Jarid2 Is Implicated in the Initial Xist-Induced Targeting of PRC2 to the Inactive X Chromosome. *Molecular Cell.* (2014).
8. Daveau, C., Baulies, S., Lalloum, M., Bollet, M., Sigal, B., Sastre, X., Vincent-Salomon, A., Tardivon, A., Thibault, F., Pierga, J.Y., Cottu, P., Sablin, M.P., Rouzier, R., Malhaire, C., Mallon, P., and **Reyal, F.** Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma. *Br. J. Cancer.* (2014).
9. Gentien, D., Kosmider, O., Nguyen-Khac, F., Albaud, B., Rapinat, A., Dumont, A.G., Damm, F., Popova, T., Marais, R., Fontenay, M., Roman Roman, S., Bernard, O.A., and Stern, M.-H. A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages. *Leukemia.* (2014).
10. Gruel, N., Benhamo, V., Bhalshankar, J., Popova, T., Fréneaux, P., Arnould, L., Mariani, O., Stern, M.-H., Raynal, V., Sastre-Garau, X., Rouzier, R., Delattre, O., and Vincent-Salomon, A. Polarity gene alterations in pure invasive micropapillary carcinomas of the breast. *Breast Cancer Res.* (2014).
11. Guimier, A., Ferrand, S., Pierron, G., Couturier, J., Janoueix-Lerosey, I., Combaret, V., Mosseri, V., Thebaud, E., Gambart, M., Plantaz, D., Marabelle, A., Coze, C., Rialland, X., Fasola, S., Lapouble, E., Fréneaux, P., Peuchmaur, M., Michon, J., Delattre, O., and **Schleiermacher, G.** Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN. *PLoS ONE.* (2014).
12. Lacoste, N., Woolfe, A., Tachiwana, H., Garea, A.V., Barth, T., Cantaloube, S., Kurumizaka, H., Imhof, A., and Almouzni, G. Mislocalization of the Centromeric Histone Variant CenH3/CENP-A in Human Cells Depends on the Chaperone DAXX. *Mol. Cell.* (2014).
13. Lefort, S., Joffre, C., Kieffer, Y., Givel, A.-M., Bourachot, B., Zago, G., Bieche, I., Dubois, T., **Meseure, D.**, Vincent-Salomon, A., Camonis, J., and Mechta-Grigoriou, F. Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers. *Autophagy.* (2014).
14. Lopez-Delisle, L., Pierre-Eugène, C., Bloch-Gallego, E., Birling, M.-C., Duband, J.-L., Durand, E., Bourgeois, T., Matrot, B., Sorg, T., Huerre, M., Meziane, H., Roux, M.J., Champy, M.-F., Gallego, J., Delattre, O., and Janoueix-Lerosey, I. Hyperactivation of Alk induces neonatal lethality in knock-in AlkF1178L mice. *Oncotarget.* (2014).
15. **Meseure, D.**, Drak Alsibai, K., and Nicolas, A. Pivotal Role of Pervasive Neoplastic and Stromal Cells Reprogramming in Circulating Tumor Cells Dissemination and Metastatic Colonization. *Cancer Microenviron.* (2014).
16. **Schleiermacher, G.**, Janoueix-Lerosey, I., and Delattre, O. Recent insights into the biology of neuroblastoma. *Int. J. Cancer.* (2014).
17. **Schleiermacher, G.**, Javanmardi, N., **Bernard, V.**, Leroy, Q., Cappel, J., Rio Frio, T., Pierron, G., Lapouble, E., Combaret, V., Speleman, F., de Wilde, B., Djos, A., Ora, I., Hedborg, F., Träger, C., Holmqvist, B.-M., Abrahamsson, J., Peuchmaur, M., Michon, J., Janoueix-Lerosey, I., Kogner, P., Delattre, O., and Martinsson, T. Emergence of New ALK Mutations at Relapse of Neuroblastoma. *J. Clin. Oncol.* (2014).
18. Theocharis, S., Kotta-Loizou, I., Klijanienko, J., Giaginis, C., Alexandrou, P., Dana, E., Rodriguez, J., Patsouris, E., and Sastre-Garau, X. Extracellular signal-regulated kinase (ERK) expression and activation in mobile tongue squamous cell carcinoma:

associations with clinicopathological parameters and patients survival. *Tumour Biol.* (2014).

19. Tirode, F., **Surdez, D.**, Ma, X., Parker, M., Deley, M.C.L., Bahrami, A., Zhang, Z., Lapouble, E., Grossetete-Lalami, S., Rusch, M., Reynaud, S., Rio-Frio, T., Hedlund, E., Wu, G., Chen, X., Pierron, G., Oberlin, O., Zaidi, S., Lemmon, G., Gupta, P., Vadodaria, B., Easton, J., Gut, M., Ding, L., Mardis, E.R., Wilson, R.K., Shurtleff, S., Laurence, V., Michon, J., Marec-Berard, P., Gut, I., Downing, J., Dyer, M., Zhang, J., and Delattre, O. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. *Cancer Discov.* (2014).

2013

1. Boeva, V., Jouannet, S., Daveau, R., Combaret, V., Pierre-Eugène, C., Cazes, A., Louis-Brennetot, C., **Schleiermacher, G.**, Ferrand, S., Pierron, G., Lermine, A., Frio, T.R., Raynal, V., Vassal, G., Barillot, E., Delattre, O., and Janoueix-Lerosey, I. Breakpoint Features of Genomic Rearrangements in Neuroblastoma with Unbalanced Translocations and Chromothripsis. *PLoS ONE.* (2013).
2. Brennan, B., Stiller, C., and **Bourdeaut, F.** Extracranial rhabdoid tumours: what we have learned so far and future directions. *Lancet Oncol.* (2013).
3. Cazes, A., Louis-Brennetot, C., Mazot, P., Dingli, F., Lombard, B., Boeva, V., Daveau, R., Cappel, J., Combaret, V., **Schleiermacher, G.**, Jouannet, S., Ferrand, S., Pierron, G., Barillot, E., Loew, D., Vigny, M., Delattre, O., and Janoueix-Lerosey, I. Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma. *Cancer Res.* (2013).
4. Furney, S.J., Pedersen, M., Gentien, D., Dumont, A.G., Rapinat, A., Desjardins, L., Turajlic, S., Piperno-Neumann, S., Grange, P. de la, Roman Roman, S., Stern, M.-H., and Marais, R. SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma. *Cancer Discov.* (2013).
5. Machado, I., Cruz, J., Lavernia, J., Rubio, L., Campos, J., Barrios, M., Grison, C., Chene, V., Pierron, G., Delattre, O., and Llombart-Bosch, A. Superficial EWSR1-negative undifferentiated small round cell sarcoma with CIC/DUX4 gene fusion: a new variant of Ewing-like tumors with locoregional lymph node metastasis. *Virchows Arch.* (2013).
6. Popova, T., Boeva, V., Elodie Manié, Rozenholc, Y., Barillot, E., and Stern, M.-H. Analysis of Somatic Alterations in Cancer Genome: From SNP Arrays to Next Generation Sequencing. (2013), iConcept Press.

2012

1. Boeva, V., Popova, T., Bleakley, K., Chiche, P., Cappel, J., **Schleiermacher, G.**, Janoueix-Lerosey, I., Delattre, O., and Barillot, E. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. *Bioinformatics.* (2012).
2. Pierron, G., Tirode, F., Lucchesi, C., Reynaud, S., Ballet, S., Cohen-Gogo, S., Perrin, V., Coindre, J.-M., and Delattre, O. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. *Nat. Genet.* (2012).
3. Postel-Vinay, S., Véron, A.S., Tirode, F., Pierron, G., Reynaud, S., Kovar, H., Oberlin, O., Lapouble, E., Ballet, S., Lucchesi, C., Kontny, U., González-Neira, A., Picci, P., Alonso, J., Patino-Garcia, A., de Paillerets, B.B., Laud, K., Dina, C., Froguel, P., Clavel-Chapelon, F., Doz, F., Michon, J., Chanock, S.J., Thomas, G., Cox, D.G., and Delattre, O. Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. *Nat. Genet.* (2012).